Theravance Biopharma TBPH Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's operating lease liabilities (current)?
- Theravance Biopharma (TBPH) reported operating lease liabilities (current) of $10.75M in Q1 2026.
- How has Theravance Biopharma's operating lease liabilities (current) changed year-over-year?
- Theravance Biopharma's operating lease liabilities (current) decreased by 0.5% year-over-year, from $10.81M to $10.75M.
- What is the long-term trend for Theravance Biopharma's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Theravance Biopharma's operating lease liabilities (current) has grown at a 2.1% compound annual growth rate (CAGR), from $9.87M to $10.95M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.